Interactions on record — worth a quick check against your medications. Check your meds →
Dietary supplement

Phosphatidic Acid Ingredients & Drug Interactions

by EPIQ

Softgel Capsule Category: Other Combinations
Most serious interaction: Moderate
The interaction bottom line Most serious interaction: Moderate

Phosphatidic Acid is a dietary supplement by EPIQ with 3 active ingredients. Its ingredients are commonly taken for low testosterone or low libido in men, male fertility support, athletic performance and muscle strength.Based on those ingredients, 451 medications have a known interaction with it, the most serious rated moderate. The ingredients most likely to interact are Long Jack root extract, Astragalus root powder. Use the checker below to test your specific medication, or read the full HelloPharmacist Interaction Report.

Computed from our clinical databases

HelloPharmacist Scorecard of Phosphatidic Acid by EPIQ

Four independent checks of what is known — a summary of the available information, not a grade of the product itself.

Evidence for Intended Use
By FDA rules, dietary supplements can’t claim to treat, cure, or prevent disease — so labels speak in careful marketing language. We discern each product’s intended use from its name, label claims, and label statements, then grade the clinical evidence for that use. How these ratings are computed
Not assessable

The stated purpose hasn't been mapped to our evidence data yet.

Why this rating?
  • We haven't mapped this product's purpose to our evidence data yet — it'll be graded on the next content refresh.
Ingredient Transparency
Low

Most active ingredients don't disclose an individual amount — you can't tell how much of each you're getting.

Why this rating?
  • The label discloses an exact amount for 0 of its 3 active ingredients.
  • “Phosphatidic Acid Complex” is a proprietary blend — the label gives one combined amount (1,529 mg) without saying how much of each component you get.
Known Interaction Concern
Moderate identified

The most serious documented interaction for these ingredients is Moderate. Check your medications for a personalized result.

Why this rating?
  • 2 of the 3 matched ingredients can interact with medications — Astragalus, Eurycoma Longifolia.
  • The most serious interaction on file is rated Moderate.
  • Some involve high-stakes drug classes: immunosuppressants / transplant drugs; diabetes medications; lithium.
  • For scale: 451 individual medications appear in the full list. A big number alone doesn't make a product dangerous — what matters is whether YOUR medication is on it, so run yours through the interaction checker on this page.
Safety Information
Well characterized

Adverse-effect, pregnancy, and general safety data are on file for most of these ingredients.

Why this rating?
  • We hold adverse-effect (side-effect) data for 3 of the 3 matched ingredients.
  • Pregnancy & breastfeeding safety ratings cover 3 of 3.
  • General safety write-ups exist for 3 of 3.
  • Remember: this measures how much safety information exists. Thin data is not the same as being safe.

HelloPharmacist summaryFormula with limited ingredient disclosure with no assessable stated purpose. Moderate medication interactions have been identified, and safety information is well characterized.

Assessment coverage: 3 of 3 active ingredients matched to our full ingredient reviews (monographs). Based on the product label dated Feb 25, 2015.

This Scorecard evaluates available label information, ingredient evidence, and known medication-safety considerations. It does not independently verify product identity, purity, potency, contamination, or manufacturing quality. How these ratings are computed

At a glance

General information

Key facts about Phosphatidic Acid, straight from the product label.

Brand EPIQ
Barcode (UPC) 631656605211
Net contents 140 Softgel(s)
Market status Off market
Date entered into DSLD Feb 25, 2015
DSLD ID 42215
Product type Other Combinations
Supplement form Softgel Capsule
Dietary claims / uses All Other, Structure/Function
Intended target group(s) Adult (18 - 50 Years)
From the label
Everything in this section is reproduced from the manufacturer’s own product label — it’s the label speaking, not HelloPharmacist. We show it so you can see exactly what the maker states; we don’t verify or endorse those statements.

Supplement Facts

The label details for Phosphatidic Acid by EPIQ, sourced from the NIH Dietary Supplement Label Database.

Supplement Facts

Daily Value (DV) Target Group(s):
Adults and children 4 or more years of age
Minimum serving Sizes:
5 Softgel(s)
Maximum serving Sizes:
5 Softgel(s)
Servings per container
28
UPC/BARCODE
631656605211
IngredientAmount% DV
Long Jack root extract0 NP--
Mediator(R) Phosphatidic Acid-enriched Soy Lecithin0 NP--
Phosphatidic Acid Complex1529 mg--
Astragalus root powder0 NP--

Other ingredients: Medium Chain Triglyceride Oil, Mono- and Diglycerides, Silicon Dioxide, Gelatin, Glycerin, Caramel color, purified Water

Tap any ingredient to jump to its full detail below.

Label statements
These statements are the manufacturer’s wording, reproduced from the product label — the label is saying it, not HelloPharmacist. We don’t verify or endorse them.
Suggested/Recommended/Usage/Directions

DIRECTIONS: Take 1 serving (5 softgels) once daily. On workout days, take 30 minutes before training. Do not exceed 5 softgels in a 24-hour period. Read the entire label before use and follow directions provided.

Precautions

WARNING: For adult use only.

Do not use if pregnant or nursing.

KEEP OUT OF REACH OF CHILDREN.

Do not use if packaging has been tampered with.

Consult a medical doctor before use if you have a medical condition or before starting a diet or exercise program. Discontinue use two weeks prior to surgery.

Contains Soy Ingredients.

Storage

Store in a cool, dark place (60(0)F to 80(0)F)

Brand IP Statement(s)

Mediator(R) PA is protected under patents pending by Chemi Nutra. Mediator(R) PA is a registered trademark of Chemi Nutra.

(C) 2014.

EPIQ(TM)is a line of powerful, effective, and guaranteed clean supplements formulated for elite athletes who demand the highest quality for EPIQ(TM) performance.

What’s more, EPIQ(TM) PHOSPHATIDIC ACID gives you the most bioavailable form of oral phosphatidic acid, and it keeps your level of phosphatidic acid raised for hours!

Start maximizing your musclebuilding potential with EPIQ(TM) PHOSPHATIDIC ACID!

STACK WITH: EPIQ(TM) SUPPLEMENT

CLEAN SUPPLEMENTS FOR EPIQ(TM) PERFORMANCE

General Statements

Made in the U.S.A. from international ingredients.

Patent pending. For lot no. and expiry date: see box.

Twitter @epiqresults Facebook.com/epiqresults

~ Developed with a scientifically researched key ingredient~ Manufactured according to current Good Manufacturing Practices (cGMP) standards, as is required for all dietary supplements ~ Made in the U.S.A. from international ingredients

100% Ultra-Pure Formula

What you’re holding in your hands is one of the most exciting new muscle and strength compounds ever researched!

Yes, you read that right – DOUBLE the gains! Want proof? 1In a recent study at the University of Tampa on 28 resistancetrained subjects, those who trained 3 times a week and took phosphatidic acid for 8 weeks actually DOUBLED the amount of muscle they gained compared to subjects following the same training protocol, but who were taking a placebo.

It’s time to truly experience results from your hard work in the gym.

~ 1In an 8-week clinical study published in Nutrition & Metabolism, resistance-trained subjects taking phosphatidic acid achieved a 100% greater increase in lean body mass and increased 1-rep max leg press by 60% more than subjects using a placebo. ~ 2In a separate phase of the same study, pre-clinical research showed that phosphatidic acid increased mTOR signalling by over 6 times compared to baseline.

SCIENTIFICALLY STUDIES KEY INGREDIENTS

4- WEEK SUPPLY

NEW!

Powerful Muscle Growth Activator

CLINICALLY DOSED KEY DRIVER

~ Subjects Gained 5.3 lbs. of Muscle in 8 Weeks,1 ~ Double Your Muscle Gains,1 ~ 60% Increase in Muscle Strength,1 ~ Increased mTOR Signalling by More Than 6 Times,2

Results based on core ingredient testing. See back of label for study details

FDA Disclaimer Statement

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

Formulation

EPIQ(TM) Guaranteed Supplements are:~ Free of banned substances ~ Free of artificial colors or dyes ~ Free of harmful impurities ~ Free of undeclared ingredients

GUARANTEED BANNED SUBSTANCE FREE

Formula

EPIQ(TM) PHOSPHATIDIC ACID contains a clinically studied musclebuilding compound that can DOUBLE your training results.

What Makes the Formula(TM)? ~ Each serving of EPIQTM PHOSPHATIDIC ACID delivers 750mg of the world’s most pure phosphatidic acid in just one serving!

Contains Soy Ingredients.

General

10341US 0914

FDA Statement of Identity

Dietary Supplement

See for yourself

Phosphatidic Acid by EPIQ label

The label scan from the NIH Dietary Supplement Label Database. Tap to enlarge.

What’s inside

The Ingredients in Phosphatidic Acid by EPIQ

These are the 3 active ingredients this product is made of. Select any to open its full monograph.

Serving size5 Softgel(s) Dosage formSoftgel Capsule Servings per container28 Amounts shown are per serving.

Most supplement products combine several ingredients, and a medication can interact with the product through any one of them. Each ingredient below shows whether it has known drug interactions.

Other (inactive) ingredients: Medium Chain Triglyceride Oil, Mono- and Diglycerides, Silicon Dioxide, Gelatin, Glycerin, Caramel color, Purified Water. These complete the product’s ingredient list but are not active constituents.

Interaction report

Phosphatidic Acid by EPIQ Drug Interactions

Phosphatidic Acid contains 3 ingredients, and 2 of them have known drug interactions. Altogether they interact with 451 medications. Here’s the picture, then you can look up your own drug.

Want to check YOUR meds against Phosphatidic Acid?

Ask about interactions with your drugs in plain English — “Can I take it with lisinopril?” — and we find you the answer in seconds, ingredient by ingredient.

Go to the checker
451Drugs
211 Moderate 240 Minor

Ingredients driving the most interactions

Each ingredient & the kinds of drugs it affects

For each ingredient in Phosphatidic Acid with known interactions, here are the types of medications they can affect. Open any type for the detail — or search your exact drug in the checker above.

Long Jack root extract5 drug types · 248 drugs

Propranolol (Inderal)

Eurycoma longifolia can reduce the levels and clinical effects of propranolol.
A small clinical study in healthy persons shows that taking a single dose of a water-based Eurycoma longifolia extract 200 mg, in combination with a single dose of propranolol 80 mg, reduces the propranolol area under the curve (AUC) by 29%, reduces the peak concentration by 42%, and increases time to peak concentration by 86% when compared with control. Since the elimination half-life of propranolol did not change, it seems that Eurycoma longifolia alters the kinetics of propranolol by decreasing its absorption in the gut, and not by altering its metabolism. It is not known if separating administration will prevent this interaction.

Likelihood Probable Evidence A
Cytochrome P450 1A2 (Cyp1A2) Substrates

Theoretically, Eurycoma longifolia might increase levels CYP1A2 substrates.
In vitro research suggests that methanolic Eurycoma longifolia root extract weakly inhibits CYP1A2 enzymes. This effect has not been reported in humans.

Likelihood Possible Evidence D
Cytochrome P450 2A6 (Cyp2A6) Substrates

Theoretically, Eurycoma longifolia might increase levels of CYP2A6 substrates.
In vitro research suggests that methanolic Eurycoma longifolia root extract weakly inhibits CYP2A6 enzymes. This effect has not been reported in humans.

Likelihood Possible Evidence D
Cytochrome P450 2C19 (Cyp2C19) Substrates

Theoretically, Eurycoma longifolia might increase levels of CYP2C19 substrates.
In vitro research suggests that methanolic Eurycoma longifolia root extract weakly inhibits CYP2C19 enzymes. This effect has not been reported in humans.

Likelihood Possible Evidence D
Testosterone

Theoretically, Eurycoma longifolia may further increase levels of testosterone.
A clinical study in aging males with testosterone levels below 300 ng/dL shows that taking a specific water extract of Eurycoma longifolia roots (Physta; Biotropics Malaysia) 100-200 mg daily with breakfast for 12 weeks increases total testosterone levels by 8% to 11% when compared with placebo. It is unclear whether this increase would occur in individuals with normal testosterone levels.

Likelihood Possible Evidence D

Astragalus root powder4 drug types · 208 drugs

Antidiabetes Drugs

Theoretically, taking astragalus with antidiabetes drugs might increase the risk of hypoglycemia.
Clinical research in humans shows that astragalus might have hypoglycemic effects. Theoretically, taking astragalus, especially in combination with other hypoglycemic agents, might increase the risk of hypoglycemia.

Likelihood Probable Evidence A
Cyclophosphamide

Theoretically, astragalus might interfere with cyclophosphamide therapy.
Evidence regarding the effect of astragalus on immunosuppression caused by cyclophosphamide is conflicting. Some animal research suggests that astragalus reverses cyclophosphamide-induced immunosuppression. However, other animal research shows no effect.

Likelihood Possible Evidence D
Immunosuppressants

Theoretically, astragalus might interfere with immunosuppressive therapy.
Astragalus seems to stimulate immune function. Theoretically, taking astragalus might decrease the effects of immunosuppressive therapy.

Likelihood Possible Evidence D
Lithium

Theoretically, astragalus might increase levels and adverse effects of lithium.
Animal research suggests that astragalus has diuretic properties. Theoretically, due to this diuretic effect, astragalus might reduce excretion and increase levels of lithium.

Likelihood Probable Evidence D
The maker

Brand information

Manufacturer and brand details for Phosphatidic Acid, from the product label.

EPIQ

See all EPIQ products
Name
Iovate Health Sciences U.S.A. Inc.
Street Address
1105 N. Market St., Ste. 1330
City
Wilmington
State
DE
ZipCode
19801
Pharmacist Counseling Corner

Phosphatidic Acid by EPIQ: Common Questions

Does Phosphatidic Acid by EPIQ interact with any medications?
Yes. Based on its ingredients, Phosphatidic Acid has a known interaction with 451 medications. Use the checker to see how it interacts with a specific drug.
How can one product interact with so many drugs?
Phosphatidic Acid contains 3 active ingredients, and an interaction can come from any of them. We check every ingredient, combine the results into one list per medication, and show which ingredient and mechanism is responsible.
Where does this information come from?
The product label data comes from the NIH Dietary Supplement Label Database (DSLD); the interaction data is built on the Natural Medicines database and reviewed by HelloPharmacist pharmacists.

Written and reviewed by the HelloPharmacist editorial staff. Our editorial policy

Not sure if Phosphatidic Acid is safe with your meds?

Our pharmacists answer your medication & supplement questions — free.

Ask a pharmacist

Label information is sourced from the NIH Dietary Supplement Label Database and reflects the product version on file; always read your actual product label. This page is for education only and is not a substitute for professional medical advice. Confirm with your pharmacist or doctor before combining supplements and medications.

Phosphatidic Acid label
Sources

Sources & How We Checked

Phosphatidic Acid's label data comes from the NIH Dietary Supplement Label Database; the ingredient interaction data is from the Natural Medicines database, reviewed by our pharmacists.

Content is written and reviewed by licensed HelloPharmacist pharmacists. See our data sources and editorial standards for how this information is built and checked.

The 26 references behind this product’s interaction data

Every citation that drives the interaction findings for this product’s ingredients, from the evidence-graded Natural Medicines (TRC Healthcare) database. Open an ingredient to browse its citations — links open the study on PubMed or the publisher’s site.

Eurycoma Longifolia 4 references
  1. Salman SA, Amrah S, Wahab MS, et al. Modification of propranolol's bioavailability by Eurycoma longifolia water-based extract. J Clin Pharm Ther 2010;35:691-6. PubMed
  2. Tambi MI, Imran MK, Henkel RR. Standardised water-soluble extract of Eurycoma longifolia, Tongkat ali, as testosterone booster for managing men with late-onset hypogonadism? Andrologia 2011 Jun 15. doi: 10.1111/j.1439-0272.2011.01168.x. [Epub ahead of pri PubMed
  3. Han YM, Kim IS, Rehman SU, Choe K, Yoo HH. In vitro evaluation of the effects of Eurycoma longifolia extract on CYP-mediated drug metabolism. Evid Based Complement Alternat Med 2015;2015:631329.
  4. Chinnappan SM, George A, Pandey P, Narke G, Choudhary YK. Effect of Eurycoma longifolia standardised aqueous root extract-Physta ® on testosterone levels and quality of life in ageing male subjects: a randomised, double-blind, placebo-controlled multicent

See these in context on the Eurycoma Longifolia monograph →

Lecithin 9 references
  1. Buchman AL, Dubin M, Jenden D, et al. Lecithin increases plasma free choline and decreases hepatic steatosis in long-term total parenteral nutrition patients. Gastroenterology 1992;102:1363-70.
  2. Food and Nutrition Board, Institute of Medicine. Dietary Reference Intakes for Thiamin, Riboflavin, Niacin, Vitamin B6, Folate, Vitamin B12, Pantothenic Acid, Biotin, and Choline (2000). Washington, DC: National Academy Press, 2000. Available at: http://b
  3. Chatellier G, Lacomblez L. Tacrine (tetrahydroaminoacridine; THA) and lecithin in senile dementia of the Alzheimer type: a multicentre trial. Groupe Francais d'Etude de la Tetrahydroaminoacridine. BMJ 1990;300:495-9.
  4. Gelenberg AJ, Dorer DJ, Wojcik JD, et al. A crossover study of lecithin treatment of tardive dyskinesia. J Clin Psychiatry 1990;51:149-53.
  5. Little A, Levy R, Chuaqui-Kidd P, Hand D. A double-blind, placebo controlled trial of high-dose lecithin in Alzheimer's disease. J Neurol Neurosurg Psychiatry 1985;48:736-42. PubMed
  6. Palm M, Moneret-Vautrin DA, Kanny G, et al. Food allergy to egg and soy lecithins. Allergy 1999;54:1116-7. PubMed
  7. Drachman DA, Glosser G, Fleming P, et al. Memory decline in the aged: treatment with lecithin and physostigmine. Neurology 1982;32:944-50. PubMed
  8. Gelenberg, A. J., Doller-Wojcik, J. C., and Growdon, J. H. Choline and lecithin in the treatment of tardive dyskinesia: preliminary results from a pilot study. Am J Psychiatry 1979;136(6):772-776. PubMed
  9. Electronic Code of Federal Regulations. Title 21, Chapter 1, Subchapter B, Part 184: Direct food substances affirmed as Generally Recognized as Safe. Subpart B - listing of specific substances affirmed as GRAS. Sec. 184.1400 Lecithin. Available at: https:

See these in context on the Lecithin monograph →

Astragalus 13 references
  1. Upton R, ed. Astragalus Root: Analytical, quality control, and therapeutic monograph. Santa Cruz, CA: American Herbal Pharmacopoeia. 1999:1-25.
  2. Khoo KS, Ang PT. Extract of astragalus membranaceus and ligustrum lucidum does not prevent cyclophosphamide-induced myelosuppression. Singapore Med J 1995;36:387-90.
  3. Chu DT, Wong WL, Mavligit GM. Immunotherapy with Chinese medicinal herbs. II. Reversal of cyclophosphamide-induced immune suppression by administration of fractionated Astragalus membranaceus in vivo. J Clin Lab Immunol 1988;25:125-9.
  4. Sun Y, Hersh EM, Lee SL, et al. Preliminary observations on the effects of the Chinese medicinal herbs Astragalus membranaceus and Ligustrum lucidum on lymphocyte blastogenic responses. J Biol Response Mod 1983;2:227-37..
  5. Ma J, Peng A, Lin S. Mechanisms of the therapeutic effect of astragalus membranaceus on sodium and water retention in experimental heart failure. Chin Med J (Engl) 1998;111:17-23.
  6. Matkovic Z, Zivkovic V, Korica M, et al. Efficacy and safety of Astragalus membranaceus in the treatment of patients with seasonal allergic rhinitis. Phytother Res 2010;24:175-81.
  7. Zhang, J. G., Yang, N., He, H., Wei, G. H., Gao, D. S., Wang, X. L., Wang, X. Z., and Song, G. Y. [Effect of Astragalus injection on plasma levels of apoptosis-related factors in aged patients with chronic heart failure.]. Chin J Integr.Med 2005;11(3):18 PubMed
  8. Chen, H. W., Lin, I. H., Chen, Y. J., Chang, K. H., Wu, M. H., Su, W. H., Huang, G. C., and Lai, Y. L. A novel infusible botanically-derived drug, PG2, for cancer-related fatigue: a phase II double-blind, randomized placebo-controlled study. Clin Invest PubMed
  9. Tian H, Lu J, He H, et al.The effect of Astragalus as an adjuvant treatment in type 2 diabetes mellitus: A (preliminary) meta-analysis. J Ethnopharmacol. 2016;191:206-215. doi: 10.1016/j.jep.2016.05.062. PubMed
  10. Hong KF, Liu PY, Zhang W, Gui DK, Xu YH. The Efficacy and Safety of Astragalus as an Adjuvant Treatment for Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis. J Integr Complement Med 2023. PubMed
  11. Chan KW, Kwong ASK, Tsui PN, et al. Add-on astragalus in type 2 diabetes and chronic kidney disease: A multi-center, assessor-blind, randomized controlled trial. Phytomedicine 2024;130:155457. PubMed
  12. Han X, Yu T, Chen X, Du Z, Yu M, Xiong J. Effect of Astragalus membranaceus on left ventricular remodeling in HFrEF: a systematic review and meta-analysis. Front Pharmacol 2024;15:1345797. PubMed
  13. Jing P, Hongzheng H, Zhenqi WU, Meijuan Z, Zuojing LI, Gang C. Long-term efficacy and safety of Huangqi ()-based Traditional Chinese Medicine in diabetic peripheral neuropathy: a Meta-analysis of randomized controlled trials. J Tradit Chin Med 2024;44(2):

See these in context on the Astragalus monograph →

Parts of this content are provided by the Therapeutic Research Center, LLC.

DISCLAIMER: Currently this does not check for drug-drug interactions. This is not an all-inclusive comprehensive list of potential interactions and is for informational purposes only. Not all interactions are known or well-reported in the scientific literature, and new interactions are continually being reported. Input is needed from a qualified healthcare provider including a pharmacist before starting any therapy. Application of clinical judgment is necessary.

© 2021 Therapeutic Research Center, LLC

Keep exploring